Comparison of PI3K Pathway in HPV-Associated Oropharyngeal Cancer With and Without Tobacco Exposure

Overview

Journal Laryngoscope Investig Otolaryngol

Publisher Wiley

Specialty Otorhinolaryngology

Date 2018 Sep 7

PMID 30186959

Citations 6

Authors

Si-Young Kiessling

Martina Anja Broglie

Alex Soltermann

Gerhard Frank Huber

Sandro Johannes Stoeckli

Affiliations

Soon will be listed here.

Abstract

Objectives: The aim of the study was to evaluate whether HPV associated OPSCC with tobacco exposure follows a different carcinogenic pathway compared to HPV associated OPSCC without tobacco exposure and to investigate its prognostic significance. The question was addressed with focus on components of the PI3K pathway.

Methods: 184 patients with newly diagnosed OPSCC treated with curative intent were consecutively enrolled. The expression level of p16, p53, PI3K, mTOR, and PTEN was assessed by immunohistochemistry and analyzed in relation to the risk factors HPV status and tobacco exposure.

Results: 94 of 184 (51%) patients were p16 positive, p53 overexpression was detected in 48 of 184 (26%) cases. PI3K overexpression with 70 of 184 (38%) cases was significantly higher in p16 positive tumors. mTOR overexpression was present in 90 of 184 (49%) cases and significantly higher in p16 negative tumors. PTEN loss was found in 42 of 184 (23%) cases without association to p16 expression. p16 positive OPSCC showed lower rates of p53 expression and mTOR expression as well as higher rates of PI3K expression irrespective of tobacco exposure. Survival analysis showed a distinct intermediate survival rate of p16 positive smokers. The markers PI3K, mTOR, and PTEN did not have a significant impact on survival.

Conclusion: HPV associated OPSCC with tobacco exposure follows the same expression level of the PI3K pathway as HPV associated OPSCC without tobacco exposure. The impaired survival rate of the intermediate risk group cannot be explained by different expression patterns of PI3K, mTOR, and PTEN.

Level Of Evidence: 2b.

Citing Articles

Clinical and molecular characteristics of Jordanian oropharyngeal cancer patients according to P16 expression: a retrospective study and a report of a novel biomarker.

Obeidat M, Algargaz W, Barukba M, Bodoor K, Mohamad I, Barakat F Med Mol Morphol. 2024; 57(2):136-146.

PMID: 38459388 DOI: 10.1007/s00795-024-00383-2.

PI3K/AKT/mTOR Signaling Pathway in HPV-Driven Head and Neck Carcinogenesis: Therapeutic Implications.

Aguayo F, Perez-Dominguez F, Osorio J, Oliva C, Calaf G Biology (Basel). 2023; 12(5).

PMID: 37237486 PMC: 10215516. DOI: 10.3390/biology12050672.

Interaction between Cigarette Smoke and Human Papillomavirus 16 E6/E7 Oncoproteins to Induce SOD2 Expression and DNA Damage in Head and Neck Cancer.

Carrillo-Beltran D, Osorio J, Blanco R, Oliva C, Boccardo E, Aguayo F Int J Mol Sci. 2023; 24(8).

PMID: 37108069 PMC: 10138975. DOI: 10.3390/ijms24086907.

An ErbB Lineage Co-Regulon Harbors Potentially Co-Druggable Targets for Multimodal Precision Therapy in Head and Neck Squamous Cell Carcinoma.

Bredel M, Kim H, Bonner J Int J Mol Sci. 2022; 23(21).

PMID: 36362284 PMC: 9658814. DOI: 10.3390/ijms232113497.

Determining the molecular landscape and impact on prognosis in HPV-associated head and neck cancer.

Khanna S, Palackdharry S, Roof L, Wicker C, Mark J, Zhu Z Cancers Head Neck. 2020; 5:11.

PMID: 32944296 PMC: 7487583. DOI: 10.1186/s41199-020-00058-2.

References

Zaravinos A . An updated overview of HPV-associated head and neck carcinomas. Oncotarget. 2014; 5(12):3956-69. PMC: 4147298. DOI: 10.18632/oncotarget.1934. View

Fruman D, Rommel C . PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014; 13(2):140-56. PMC: 3994981. DOI: 10.1038/nrd4204. View

Lui V, Hedberg M, Li H, Vangara B, Pendleton K, Zeng Y . Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 2013; 3(7):761-9. PMC: 3710532. DOI: 10.1158/2159-8290.CD-13-0103. View

Munger K, Howley P . Human papillomavirus immortalization and transformation functions. Virus Res. 2002; 89(2):213-28. DOI: 10.1016/s0168-1702(02)00190-9. View

Chun S, Jung C, Won H, Kang J, Kim Y, Kim M . Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer. Head Neck. 2014; 37(5):636-43. DOI: 10.1002/hed.23643. View

Shi W, Kato H, Perez-Ordonez B, Pintilie M, Huang S, Hui A . Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol. 2009; 27(36):6213-21. DOI: 10.1200/JCO.2009.23.1670. View

Hafkamp H, Speel E, Haesevoets A, Bot F, Dinjens W, Ramaekers F . A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer. 2003; 107(3):394-400. DOI: 10.1002/ijc.11389. View

Chung C, Gillison M . Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res. 2009; 15(22):6758-62. DOI: 10.1158/1078-0432.CCR-09-0784. View

Lassen P, Eriksen J, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J . Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol. 2009; 27(12):1992-8. DOI: 10.1200/JCO.2008.20.2853. View

10.

Cai Y, Dodhia S, Su G . Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma. Oncotarget. 2017; 8(13):22203-22217. PMC: 5400658. DOI: 10.18632/oncotarget.14729. View

11.

Fakhry C, Westra W, Li S, Cmelak A, Ridge J, Pinto H . Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008; 100(4):261-9. DOI: 10.1093/jnci/djn011. View

12.

Trigka E, Levidou G, Saetta A, Chatziandreou I, Tomos P, Thalassinos N . A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features. Oncol Rep. 2013; 30(2):623-36. DOI: 10.3892/or.2013.2512. View

13.

Weinberger P, Yu Z, Haffty B, Kowalski D, Harigopal M, Brandsma J . Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 2006; 24(5):736-47. DOI: 10.1200/JCO.2004.00.3335. View

14.

Leemans C, Braakhuis B, Brakenhoff R . The molecular biology of head and neck cancer. Nat Rev Cancer. 2010; 11(1):9-22. DOI: 10.1038/nrc2982. View

15.

Liu P, Cheng H, Roberts T, Zhao J . Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8(8):627-44. PMC: 3142564. DOI: 10.1038/nrd2926. View

16.

Thorpe L, Yuzugullu H, Zhao J . PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2014; 15(1):7-24. PMC: 4384662. DOI: 10.1038/nrc3860. View

17.

Liontos M, Trigka E, Korkolopoulou P, Tzannis K, Lainakis G, Koutsoukos K . Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients. World J Urol. 2016; 35(3):411-419. DOI: 10.1007/s00345-016-1890-7. View

18.

Martin D, Abba M, Molinolo A, Vitale-Cross L, Wang Z, Zaida M . The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies. Oncotarget. 2014; 5(19):8906-23. PMC: 4253406. DOI: 10.18632/oncotarget.2417. View

19.

Maxwell J, Kumar B, Feng F, Worden F, Lee J, Eisbruch A . Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res. 2010; 16(4):1226-35. PMC: 2822887. DOI: 10.1158/1078-0432.CCR-09-2350. View

20.

Tomaic V, Pim D, Thomas M, Massimi P, Myers M, Banks L . Regulation of the human papillomavirus type 18 E6/E6AP ubiquitin ligase complex by the HECT domain-containing protein EDD. J Virol. 2011; 85(7):3120-7. PMC: 3067830. DOI: 10.1128/JVI.02004-10. View